Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data.

Early consideration of the multiplicity of factors that govern the biological fate of foreign compounds in living systems is a necessary prerequisite for the quantitative in vitro-in vivo extrapolation (QIVIVE) of toxicity data. Substantial technological advances in in vitro methodologies have facilitated the study of in vitro metabolism and the further use of such data for in vivo prediction. However, extrapolation to in vivo with a comfortable degree of confidence, requires continuous progress in the field to address challenges such as e.g., in vitro evaluation of chemical-chemical interactions, accounting for individual variability but also analytical challenges for ensuring sensitive measurement technologies. This paper discusses the current status of in vitro metabolism studies for QIVIVE extrapolation, serving today's hazard and risk assessment needs. A short overview of the methodologies for in vitro metabolism studies is given. Furthermore, recommendations for priority research and other activities are provided to ensure further widespread uptake of in vitro metabolism methods in 21st century toxicology. The need for more streamlined and explicitly described integrated approaches to reflect the physiology and the related dynamic and kinetic processes of the human body is highlighted i.e., using in vitro data in combination with in silico approaches.

[1]  Catarina Brito,et al.  Human liver cell spheroids in extended perfusion bioreactor culture for repeated‐dose drug testing , 2012, Hepatology.

[2]  F. Jordán,et al.  Models of the ecological hierarchy : from molecules to the ecosphere , 2012 .

[3]  Dennis A. Smith,et al.  Evolution of ADME science: where else can modeling and simulation contribute? , 2013, Molecular pharmaceutics.

[4]  Hugues Dolgos,et al.  Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development , 2013, Drug Metabolism and Disposition.

[5]  Hans Clevers,et al.  In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration , 2013, Nature.

[6]  Paolo Benedetti,et al.  Exposition and reactivity optimization to predict sites of metabolism in chemicals. , 2013, Drug discovery today. Technologies.

[7]  I. Wilson,et al.  In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid , 2013, Archives of Toxicology.

[8]  E. Testai,et al.  The contribution of human small intestine to chlorpyrifos biotransformation. , 2012, Toxicology letters.

[9]  T. Mauriala,et al.  Mass spectrometric tools for cell and tissue studies. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[10]  Melvin E. Andersen,et al.  Organotypic liver culture models: Meeting current challenges in toxicity testing , 2012, Critical reviews in toxicology.

[11]  Roy J. Vaz,et al.  The challenges of in silico contributions to drug metabolism in lead optimization , 2010, Expert opinion on drug metabolism & toxicology.

[12]  P. Olinga,et al.  Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies , 2010, Nature Protocols.

[13]  A. Boobis,et al.  Local Kinetics and Dynamics of Xenobiotics , 2008, Critical reviews in toxicology.

[14]  Angus Nedderman,et al.  Analytical strategies for identifying drug metabolites. , 2007, Mass spectrometry reviews.

[15]  J. Houston,et al.  Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: clearance-dependent relationship and implications for prediction of in vivo clearance , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  Benoît Schilter,et al.  A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. , 2008, Toxicology and applied pharmacology.

[17]  Patricia Wright,et al.  Metabolite identification by mass spectrometry: forty years of evolution , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[18]  Andreas Bender,et al.  Computational Prediction of Metabolism: Sites, Products, SAR, P450 Enzyme Dynamics, and Mechanisms , 2012, J. Chem. Inf. Model..

[19]  T. Andersson,et al.  Cytochrome P450-Dependent Metabolism in HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor , 2011, Drug Metabolism and Disposition.

[20]  H. Toutain,et al.  Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. , 2000, Toxicology.

[21]  Harvey J Clewell,et al.  PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. , 2014, Regulatory toxicology and pharmacology : RTP.

[22]  Hannu Raunio,et al.  From known knowns to known unknowns: predicting in vivo drug metabolites. , 2009, Bioanalysis.

[23]  P. Bachellier,et al.  Plateable cryopreserved human hepatocytes for the assessment of cytochrome P450 inducibility: experimental condition-related variables affecting their response to inducers , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  U. Müller-Vieira,et al.  Serum‐free culture of primary human hepatocytes in a miniaturized hollow‐fibre membrane bioreactor for pharmacological in vitro studies , 2015, Journal of Tissue Engineering and Regenerative Medicine.

[25]  Sandra Coecke,et al.  Three-dimensional HepaRG model as an attractive tool for toxicity testing. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  P. Georgopoulos,et al.  Tissue-Level Modeling of Xenobiotic Metabolism in Liver: An Emerging Tool for Enabling Clinical Translational Research , 2022 .

[27]  Paavo Honkakoski,et al.  Inhibition and induction of human cytochrome P450 enzymes: current status , 2008, Archives of Toxicology.

[28]  A. Ahluwalia,et al.  Modular bioreactor for primary human hepatocyte culture: Medium flow stimulates expression and activity of detoxification genes , 2011, Biotechnology journal.

[29]  P. Maurel Drug metabolizing enzymes , 1998 .

[30]  J. Houston,et al.  Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  H. Tumen,et al.  Pregnancy and chronic ulcerative colitis. , 1950, Gastroenterology.

[32]  E. Bonnin,et al.  An integrative in vitro approach to analyse digestion of wheat polysaccharides and the effect of enzyme supplementation , 2011, British Journal of Nutrition.

[33]  Xavier Stéphenne,et al.  Hepatocyte cryopreservation: is it time to change the strategy? , 2010, World journal of gastroenterology.

[34]  Hyun Uk Kim,et al.  Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. , 2010, Metabolic engineering.

[35]  Francesca Caloni,et al.  Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human? , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[36]  Thomas A. Louis,et al.  The Future Use of in Vitro Data in Risk Assessment to Set Human Exposure Standards: Challenging Problems and Familiar Solutions , 2010, Environmental health perspectives.

[37]  Harvey J Clewell,et al.  Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[38]  Ursula Gundert-Remy,et al.  Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda , 2007, Alternatives to laboratory animals : ATLA.

[39]  O. Pelkonen,et al.  Analytical challenges for conducting rapid metabolism characterization for QIVIVE. , 2015, Toxicology.

[40]  F. Russel,et al.  Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  W. Dekant The role of biotransformation and bioactivation in toxicity. , 2009, EXS.

[42]  F. Williams Potential for metabolism locally in the skin of dermally absorbed compounds , 2008, Human & experimental toxicology.

[43]  Sandra Coecke,et al.  Comparison of metabolic stability and metabolite identification of 55 ECVAM/ICCVAM validation compounds between human and rat liver homogenates and microsomes - a preliminary analysis. , 2009, ALTEX.

[44]  C. Yap,et al.  Pharmaceutical metabolite profiling using quadrupole/ion mobility spectrometry/time-of-flight mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[45]  Takanori Takebe,et al.  Vascularized and functional human liver from an iPSC-derived organ bud transplant , 2013, Nature.

[46]  K. Brouwer,et al.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity , 2010, Drug metabolism reviews.

[47]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[48]  Arnaud Tonnelier,et al.  Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model , 2011, Archives of Toxicology.

[49]  A. Guillouzo,et al.  Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[50]  F. Guengerich Cytochrome p450 and chemical toxicology. , 2008, Chemical research in toxicology.

[51]  Robert J Kavlock,et al.  Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[52]  Yuko Ito,et al.  Human CYPs involved in drug metabolism: structures, substrates and binding affinities , 2010, Expert opinion on drug metabolism & toxicology.

[53]  Mingshe Zhu,et al.  Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites. , 2009, Chemico-biological interactions.

[54]  Adam S. Hayward,et al.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME , 2013, Archives of Toxicology.

[55]  Bruno Sarmento,et al.  Models to predict intestinal absorption of therapeutic peptides and proteins. , 2012, Current drug metabolism.

[56]  Andrew Worth,et al.  Metabolism: A Bottleneck in In Vitro Toxicological Test Development , 2006, Alternatives to laboratory animals : ATLA.

[57]  Richard S. Judson,et al.  Modeling In Vitro Cell-Based Assays Experiments: Cell Population Dynamics , 2012 .

[58]  Urs A Meyer,et al.  Omics and drug response. , 2013, Annual review of pharmacology and toxicology.

[59]  O. Pelkonen,et al.  Hepatocytes: the powerhouse of biotransformation. , 2012, The international journal of biochemistry & cell biology.

[60]  M. Monshouwer,et al.  Determination of Time-Dependent Inactivation of CYP3A4 in Cryopreserved Human Hepatocytes and Assessment of Human Drug-Drug Interactions , 2011, Drug Metabolism and Disposition.

[61]  Alessandro Pedretti,et al.  Reactions and enzymes in the metabolism of drugs and other xenobiotics. , 2012, Drug discovery today.

[62]  J Brian Houston,et al.  Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.

[63]  Hung-Chih Kuo,et al.  Rapid generation of mature hepatocyte‐like cells from human induced pluripotent stem cells by an efficient three‐step protocol , 2012, Hepatology.

[64]  P. Bachellier,et al.  Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - a European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[65]  A. Vickers,et al.  Organ slices for the evaluation of human drug toxicity. , 2004, Chemico-biological interactions.

[66]  P. Alves,et al.  Towards an extended functional hepatocyte in vitro culture. , 2009, Tissue engineering. Part C, Methods.

[67]  J. Venitz,et al.  Preclinical Disposition (In Vitro) of Novel μ-Opioid Receptor Selective Antagonists , 2011, Drug Metabolism and Disposition.

[68]  Ian D. Wilson,et al.  Managing the challenge of chemically reactive metabolites in drug development , 2011, Nature Reviews Drug Discovery.

[69]  Carl-Fredrik Mandenius,et al.  Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines — A Report on the Vitrocellomics EU-project , 2011, Alternatives to laboratory animals : ATLA.

[70]  Hiroshi Yamazaki,et al.  Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. , 2010, Current drug metabolism.

[71]  O. Pelkonen,et al.  Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[72]  M. Ierapetritou,et al.  Analysis of amino acid supplementation effects on hepatocyte cultures using flux balance analysis. , 2011, Omics : a journal of integrative biology.

[73]  S. Haddad,et al.  Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. , 2013, Journal of pharmaceutical sciences.

[74]  Harvey J Clewell,et al.  Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.

[75]  Yan Li,et al.  Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. , 2011, Chemico-biological interactions.

[76]  Bas J Blaauboer,et al.  The contribution of in vitro toxicity data in hazard and risk assessment: current limitations and future perspectives. , 2008, Toxicology letters.

[77]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[78]  M. Schwab,et al.  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.

[79]  Klaus Mauch,et al.  A Multi-Scale Modeling Framework for Individualized, Spatiotemporal Prediction of Drug Effects and Toxicological Risk , 2013, Front. Pharmacol..

[80]  J. Castro-Pérez,et al.  High-resolution chromatography/time-of-flight MSE with in silico data mining is an information-rich approach to reactive metabolite screening. , 2011, Rapid communications in mass spectrometry : RCM.

[81]  Claus-Michael Lehr,et al.  An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[82]  O. Hovatta,et al.  Improved cryopreservation of human hepatocytes using a new xeno free cryoprotectant solution. , 2012, World journal of hepatology.

[83]  D. Goldstein,et al.  CYP2C9*1B Promoter Polymorphisms, in Linkage with CYP2C19*2, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose , 2010, Journal of Pharmacology and Experimental Therapeutics.

[84]  Thomas Schreiter,et al.  Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. , 2011, Tissue engineering. Part C, Methods.

[85]  Valérie Zuang,et al.  Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010 , 2011, Archives of Toxicology.

[86]  M. Ingelman-Sundberg,et al.  Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy , 2007, Expert opinion on therapeutic targets.

[87]  Ismael Zamora,et al.  Enhanced metabolite identification with MS(E) and a semi-automated software for structural elucidation. , 2010, Rapid communications in mass spectrometry : RCM.

[88]  L. Wienkers,et al.  Application of cytochrome P450 drug interaction screening in drug discovery. , 2010, Combinatorial chemistry & high throughput screening.

[89]  Ugo Zanelli,et al.  Comparison of Cryopreserved HepaRG Cells with Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs , 2012, Drug Metabolism and Disposition.

[90]  P. Nieminen,et al.  Estimation of health risk by using toxicokinetic modelling: a case study of polychlorinated biphenyl PCB153. , 2013, Journal of hazardous materials.

[91]  O. Pelkonen,et al.  In vitro–in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions and correct concentrations , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[92]  E. Testai,et al.  Caco 2/TC7 cell line chracterization for intestinal absorption : a reliable in vitro model for the prediction of the oral dose fraction absorbed in human , 2008 .

[93]  J. Houston,et al.  Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.

[94]  A. Taniguchi,et al.  [Development of novel culture system using nano-biotechnology]. , 2010, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[95]  Haishan Wang,et al.  Preclinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics , 2011, Drug Metabolism and Disposition.

[96]  A. Guillouzo,et al.  Running title page Running title : Functional stability of CYP P 450 enzymes in HepaRG cells , 2009 .

[97]  Z. Dvořák,et al.  Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes , 2011, Front. Pharmacol..

[98]  K. Vähäkangas,et al.  Preservation, induction or incorporation of metabolism into the in vitro cellular system - views to current opportunities and limitations. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[99]  Bas J Blaauboer,et al.  The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. , 2012, ALTEX.

[100]  T. Rushmore,et al.  Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[101]  J Scheel,et al.  Report from the EPAA workshop: in vitro ADME in safety testing used by EPAA industry sectors. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[102]  Chuang Lu,et al.  The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.

[103]  J. Ambroso,et al.  Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. , 2012, Chemical research in toxicology.

[104]  S. Krähenbühl,et al.  The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. , 2011, Biochemical pharmacology.

[105]  Carolyn Vickers,et al.  Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. , 2011, Regulatory toxicology and pharmacology : RTP.

[106]  Bruno Sarmento,et al.  Cell-based in vitro models for predicting drug permeability , 2012, Expert opinion on drug metabolism & toxicology.

[107]  D. Howes,et al.  Percutaneous penetration and dermal metabolism of triclosan (2,4, 4'-trichloro-2'-hydroxydiphenyl ether). , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[108]  Jörg C Gerlach,et al.  HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.

[109]  J. Sahi,et al.  Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery. , 2010, Current drug discovery technologies.

[110]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[111]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[112]  George Loizou,et al.  Toxicokinetics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.

[113]  M. Vidyavathi,et al.  Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review , 2010, Applied biochemistry and biotechnology.

[114]  T. Baillie,et al.  Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. , 2008, Chemical research in toxicology.

[115]  J. Mak,et al.  In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability , 2013, Expert opinion on drug metabolism & toxicology.

[116]  S. Reichl,et al.  Cultivation of RPMI 2650 cells as an in‐vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions , 2012, The Journal of pharmacy and pharmacology.

[117]  C. Lehr,et al.  A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[118]  Alicia Paini,et al.  In vivo validation of DNA adduct formation by estragole in rats predicted by physiologically based biodynamic modelling. , 2012, Mutagenesis.

[119]  F. Sonntag,et al.  A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. , 2013, Lab on a chip.

[120]  L. Ståhle,et al.  Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data , 2013, European Journal of Clinical Pharmacology.

[121]  M. Ierapetritou,et al.  A Rational Design Approach for Amino Acid Supplementation in Hepatocyte Culture , 2009 .

[122]  P. Prusis,et al.  Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[123]  Tommy B Andersson,et al.  Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies , 2008, Drug Metabolism and Disposition.

[124]  Y. Wong,et al.  Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species , 2011, Cancer Chemotherapy and Pharmacology.

[125]  Bas J Blaauboer,et al.  Biokinetic Modeling and in Vitro–in Vivo Extrapolations , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[126]  Bálint Sinkó,et al.  Skin-PAMPA: a new method for fast prediction of skin penetration. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[127]  P. Olinga,et al.  Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.